Blog

Gordagen Receives AUD$1.3M R&D Tax Incentive

Gordagen Pharmaceuticals, a private Australian company developing biopharmaceuticals and nutraceuticals based on the medicinal properties of tocotrienols, is pleased to announce it has received a Research and Development Tax Incentive Refund of AUD$1.3 million for the 2015/2016 financial…

Fight Club – A Personal Account of Immunotherapy Treatment in Melbourne

A personal journey illustrating the potential benefits of immunotherapy and also  featuring several  leading oncology practitioners based in Melbourne When Steven Jones-Evans was diagnosed with bladder cancer, the prognosis was grim. His only hope was new – and expensive…

Stopping superbugs with a protective coat – CSIRO

Around the world 700,000 people die of drug resistant infections a year, and that figure could rise to 10 million a year by 2050. The resulting financial cost is predicted to reach $100 trillion USD. It’s a global problem…

AdAlta Ltd lists on the ASX

Melbourne-based company, and BioMelbourne Network Member,  AdAlta Limited has listed on the ASX. AdAlta is a drug discovery and development company focused on using its powerful technology platform to generate a promising new class of protein therapeutics, known…

Australian protein discovery leads to tablet that “melts away blood cancer”

A potent anti-cancer treatment co-developed and trialled in Melbourne has been granted approval for use in patients by the powerful US Food and Drug Administration (FDA). The announcement recognises that the drug, venetoclax, is a successful new therapy…

He makes 3D skull and bone implants but now he’s in pain

Melbourne neurosurgeon Paul d’Urso founded Anatomics 20 years ago to make customised 3D print cranial implants. With the advent of new, stronger materials such as powdered titanium Anatomics  has expanded the range to load bearing spinal, heel and…

Medicinal cannabis startup LeafCann hopes to secure first Australian licence to establish trial crops in regional Victoria

Since Victoria has become the first Australian state to legalise the manufacture and supply of cannabis for medicinal and scientific purposes, cultivators have begun the lengthy process of securing an Australian licence. Chris Nasr is one such cultivator…

First 3D map of cell-building protein linked to cancer

Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. The unprecedented view of the protein doublecortin…

Alzheimer’s disease drug study by Melbourne researchers shows promise

A trial of a new drug to treat Alzheimer’s disease has revealed it to be safe and well tolerated in patients, while showing promising signs it could slow the spread of the neurological disease.Patients diagnosed with the most…

First 3D map of cell-building protein linked to cancer

Walter and Eliza Hall Institute researchers have revealed for the first time the three-dimensional molecular ‘map’ of a protein that has been pinpointed as a driver of many types of cancers. More than one in 10 stomach cancers…

Federal government’s Biomedical fund addresses market failure

Venture capitalists and institutional investors are keen to back a new $250 million federal government venture fund that aims to invest in promising biomedical discoveries and keep funding them until they become global giants.The Biomedical Translation Fund (BTF),…

Preparing For Proton Beam Therapy Cancer Boost

Victoria has provided $50 million in funding towards establishing a National Proton Beam Therapy Centre for the treatment of cancer in Melbourne. Minister for Health, Jill Hennessy, made the announcement while touring the construction of University College London…

Home

News & opinion

Member Directory

Events